Open access
Sep 2026
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
BACKGROUND/OBJECTIVES Tirzepatide is a once-weekly, glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) for obesity treatment. This indirect treatment comparison (ITC) assessed the relative efficacy and safety of tirzepatide versus the GLP-1 RA semaglutide. SUBJECTS/...
A. Ciudin, Erin Johansson, S. Zimner-Rapuch et al.
· International Journal of Obe... · 0 citations